A similar study involving EGFR mutation in epidermoid carcinoma showed that treatment of EGFR‐driven tumor cells with canertinib and dacomitinib, but not with anti‐EGFR antibody (cetuximab) or etoposide, increased the release of exosome‐like EVs containing EGFR and gDNA. This evidence concerns the gene EGFR and neoplasm.